Bryn Mawr Capital Management LLC Has $475,000 Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Bryn Mawr Capital Management LLC increased its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 109.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,070 shares of the medical research company’s stock after acquiring an additional 1,081 shares during the quarter. Bryn Mawr Capital Management LLC’s holdings in Laboratory Co. of America were worth $475,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. State Street Corp increased its stake in Laboratory Co. of America by 0.7% during the third quarter. State Street Corp now owns 3,726,627 shares of the medical research company’s stock valued at $832,827,000 after acquiring an additional 25,469 shares during the period. Diamond Hill Capital Management Inc. boosted its holdings in shares of Laboratory Co. of America by 1.5% in the 3rd quarter. Diamond Hill Capital Management Inc. now owns 1,978,686 shares of the medical research company’s stock worth $442,197,000 after acquiring an additional 29,046 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Laboratory Co. of America by 0.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,964,743 shares of the medical research company’s stock worth $437,561,000 after acquiring an additional 13,298 shares in the last quarter. JPMorgan Chase & Co. lifted its holdings in Laboratory Co. of America by 9.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,930,395 shares of the medical research company’s stock worth $431,405,000 after buying an additional 167,137 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its holdings in Laboratory Co. of America by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,916,505 shares of the medical research company’s stock worth $437,357,000 after buying an additional 51,045 shares in the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Wall Street Analyst Weigh In

LH has been the topic of a number of analyst reports. Evercore ISI raised Laboratory Co. of America from an “in-line” rating to an “outperform” rating and increased their price target for the company from $260.00 to $265.00 in a research note on Tuesday, January 7th. Bank of America increased their target price on Laboratory Co. of America from $262.00 to $271.00 and gave the stock a “buy” rating in a report on Friday, December 13th. Piper Sandler increased their target price on Laboratory Co. of America from $240.00 to $260.00 and gave the stock a “neutral” rating in a report on Monday, February 10th. Jefferies Financial Group increased their target price on Laboratory Co. of America from $275.00 to $290.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Finally, StockNews.com upgraded Laboratory Co. of America from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Laboratory Co. of America presently has a consensus rating of “Moderate Buy” and a consensus price target of $265.75.

Insiders Place Their Bets

In other Laboratory Co. of America news, CMO Amy B. Summy sold 226 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $250.40, for a total transaction of $56,590.40. Following the completion of the sale, the chief marketing officer now directly owns 4,544 shares in the company, valued at $1,137,817.60. This trade represents a 4.74 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Dwight Gary Gilliland sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $241.00, for a total transaction of $241,000.00. Following the sale, the director now owns 7,712 shares of the company’s stock, valued at $1,858,592. This trade represents a 11.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 21,372 shares of company stock worth $5,175,793 over the last three months. Insiders own 0.85% of the company’s stock.

Laboratory Co. of America Price Performance

Shares of NYSE LH opened at $247.89 on Friday. Laboratory Co. of America Holdings has a fifty-two week low of $191.97 and a fifty-two week high of $258.59. The stock has a market capitalization of $20.73 billion, a price-to-earnings ratio of 28.11, a PEG ratio of 1.71 and a beta of 1.07. The business has a 50-day moving average of $240.74 and a 200-day moving average of $232.44. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.44 and a quick ratio of 1.30.

Laboratory Co. of America (NYSE:LH) last issued its earnings results on Thursday, February 6th. The medical research company reported $3.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.40 by $0.05. Laboratory Co. of America had a net margin of 5.73% and a return on equity of 15.29%. As a group, sell-side analysts predict that Laboratory Co. of America Holdings will post 16.01 earnings per share for the current fiscal year.

Laboratory Co. of America Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, March 12th. Investors of record on Thursday, February 27th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Thursday, February 27th. This represents a $2.88 annualized dividend and a yield of 1.16%. Laboratory Co. of America’s dividend payout ratio (DPR) is currently 32.65%.

About Laboratory Co. of America

Labcorp Holdings, Inc engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.